Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to $205418.0.

  • Aytu Biopharma's Gains from Investment Securities fell 721.53% to $205418.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $205418.0, marking a year-over-year decrease of 721.53%. This contributed to the annual value of $211618.0 for FY2025, which is 4441.07% up from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Gains from Investment Securities is $205418.0, which was down 721.53% from $206800.0 recorded in Q3 2025.
  • Aytu Biopharma's Gains from Investment Securities' 5-year high stood at $1.0 million during Q2 2024, with a 5-year trough of -$2.7 million in Q2 2021.
  • Moreover, its 5-year median value for Gains from Investment Securities was $141439.0 (2024), whereas its average is -$98975.7.
  • The largest annual percentage gain for Aytu Biopharma's Gains from Investment Securities in the last 5 years was 418225.85% (2023), contrasted with its biggest fall of 9630000.0% (2023).
  • Aytu Biopharma's Gains from Investment Securities (Quarter) stood at $277000.0 in 2021, then crashed by 80.92% to $52861.0 in 2022, then skyrocketed by 182.04% to $149087.0 in 2023, then surged by 48.5% to $221392.0 in 2024, then fell by 7.22% to $205418.0 in 2025.
  • Its Gains from Investment Securities stands at $205418.0 for Q4 2025, versus $206800.0 for Q3 2025 and $219244.0 for Q1 2025.